In accordance with Anika’s commitment to return capital to shareholders while maintaining the flexibility to execute on strategic growth objectives, the Company is commencing a $15 million 10b5-1 share repurchase which it expects to complete by June 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK:
- Anika Therapeutics reports Q3 adjusted EPS 4c vs. 7c last year
- Is ANIK a Buy, Before Earnings?
- Anika Therapeutics’ Integrity Implant System Study: A Market Game Changer?
- Anika Therapeutics: Undervalued Stock with Potential Upside Amidst Execution Challenges